Jonathan A Chatzkel, M.D.
Assistant Professor
Department:
MD-HEMATOLOGY/ONCOLOGY
Business Phone:
(352) 273-7832
Business Email:
jonathanchatzkel@ufl.edu
About Jonathan A Chatzkel
Jonathan Chatzkel, MD is an assistant professor of medicine in the division of hematology and oncology at the University of Florida College of Medicine. Dr. Chatzkel attended the University of Pennsylvania where he graduated magna cum laude, receiving a Bachelors of Arts degree with honors in Economics. He completed his medical degree at the Perelman School of Medicine at the University of Pennsylvania, followed by an internal medicine residency at Washington University in St. Louis, MO and a hematology and oncology fellowship at the Moffitt Cancer Center in Tampa, FL. Dr. Chatzel’s clinical interests include the care of patients with genitourinary cancers, including cancers of the kidney, bladder, prostate, and testis. He believes strongly in delivering individualized care to each of his patients. Professional affiliations include the American Society of Clinical Oncology, or ASCO.
Accomplishments
Max Kade Fellow
2013
·
American Austrian Foundation/ Max Kade Foundation
Teaching Profile
Courses Taught
2024
BMS6632 Endo and Reproduction
Board Certifications
-
Internal MedicineAmerican Board of Internal Medicine
-
Medical LicenseFlorida Medical Association
-
Medical OncologyAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Cancer
- Hematology and Oncology
Areas of Interest
- Bladder Cancer
- Gastrointestinal cancer
- Kidney cancer
- Prostate Cancer
- Testicular cancer
Research Profile
Areas of Interest
- Biomarkers Response to Radium-223
- Cell Pathology
- Prostate Cancer
Publications
2023
A nurse-led intervention in patients with newly diagnosed cancer and Type 2 diabetes: A pilot randomized controlled trial feasibility study.
Cancer medicine.
12(11):12874-12880
[DOI] 10.1002/cam4.6118.
[PMID] 37212484.
2022
Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial.
Future oncology (London, England).
[DOI] 10.2217/fon-2022-0392.
[PMID] 36399037.
2022
Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer.
Clinical genitourinary cancer.
20(3):252-259
[DOI] 10.1016/j.clgc.2022.01.010.
[PMID] 35249821.
2022
Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
Cancers.
15(1)
[DOI] 10.3390/cancers15010168.
[PMID] 36612164.
2022
Tivozanib for the treatment of advanced renal cell carcinoma.
Expert opinion on pharmacotherapy.
23(10):1135-1142
[DOI] 10.1080/14656566.2022.2102419.
[PMID] 35848061.
2021
Immunotherapy Management in Special Cancer Patient Populations.
JCO oncology practice.
17(5):240-245
[DOI] 10.1200/OP.20.00996.
[PMID] 33710933.
2021
Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma.
Cancers.
13(22)
[DOI] 10.3390/cancers13225856.
[PMID] 34831009.
2019
Circulating tumor cells and γH2AX as biomarkers for responsiveness to radium-223 in advanced prostate cancer patients.
Future science OA.
6(1)
[DOI] 10.2144/fsoa-2019-0092.
[PMID] 31915536.
2017
Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma.
Head and neck pathology.
11(3):338-345
[DOI] 10.1007/s12105-016-0775-9.
[PMID] 28025779.
2014
Expiratory air trapping on thoracic computed tomography. A diagnostic subclassification.
Annals of the American Thoracic Society.
11(6):874-81
[DOI] 10.1513/AnnalsATS.201311-390OC.
[PMID] 24956379.
2012
Red nucleus degeneration in hypertrophic olivary degeneration after pediatric posterior fossa tumor resection: use of susceptibility-weighted imaging (SWI).
Pediatric radiology.
42(4):481-5
[DOI] 10.1007/s00247-011-2330-x.
[PMID] 22218736.
2010
Metronidazole-induced cerebellar toxicity.
Pediatric radiology.
40(8)
[DOI] 10.1007/s00247-009-1453-9.
[PMID] 19915830.
Grants
Jan 2023
ACTIVE
Exploring novel therapeutic strategies for combinatory therapy to treat renal clear cell carcinomas
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Oct 2022
ACTIVE
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO
via EXELIXIS
Sep 2021
ACTIVE
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Role: Principal Investigator
Funding: AVEO PHARMACEUTICALS
May 2021
ACTIVE
A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)
Role: Principal Investigator
Funding: Merck Sharp & Dohme
Apr 2021
ACTIVE
PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via JANSSEN PHARMACEUTICA INC
Dec 2020
ACTIVE
PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Mar 2020
ACTIVE
PD-INHIBITOR (NIVOLUMAB) AND IPILIMUMAB FOLLOWED BY NIVOLUMAB VS. VEGF TKI CABOZANTINIB WITH NIVOLUMAB: A PHASE III TRIAL IN METASTATIC UNTREATED RENAL CELL CANCER [PDIGREE]
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY
Sep 2019
ACTIVE
A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Sep 2019
ACTIVE
A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
May 2019
ACTIVE
PD-INHIBITOR (NIVOLUMAB) AND IPILIMUMAB FOLLOWED BY NIVOLUMAB VS. VEGF TKI CABOZANTINIB WITH NIVOLUMAB: A PHASE III TRIAL IN METASTATIC UNTREATED RENAL CELL CANCER [PDIGREE]
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Mar 2019
ACTIVE
PHASE III RANDOMIZED ADJUVANT STUDY OF MK-3475 (PEMBROLIZUMAB) IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA (AMBASSADOR) VERSUS OBSERVATION
Role: Principal Investigator
Funding: ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY
via NATL INST OF HLTH NCI
Education
Fellowship, Hematology – Oncology
2016-2019
·
Moffitt Cancer Center
Residency, Internal Medicine
2013-2016
·
Washington University, St. Louis
Medical School, Doctor of Medicine
2008-2013
·
Perleman School of Medicine at the University of Pennsylvania
Honors Bachelors of Arts, Economics
2000-2004
·
University of Pennsylvania
Contact Details
Phones:
- Business:
- (352) 273-7832
Emails:
- Business:
- jonathanchatzkel@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100278
GAINESVILLE FL 32610 - Business Street:
-
PO Box 110278
GAINESVILLE FL 32611